Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 4/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25115993 | 0.93 | GABRA5 (0.33) | GABRA5LMNAMAPT | |
| SCHEMBL23905403 | 0.90 | AR (0.35) | SSTR5KCNH2AR | |
| SCHEMBL25117183 | 0.89 | SSTR5 (0.31) | GABRA5SSTR5AR | |
| SCHEMBL23905415 | 0.88 | GABRA5 (0.32) | GABRA5AR | |
| SCHEMBL24987243 | 0.87 | GABRA5 (0.34) | GABRA5SSTR5KCNH2AR | |
| SCHEMBL23905718 | 0.86 | CFTR (0.32) | GABRA5MAPT | |
| SCHEMBL23905489 | 0.85 | GABRA5 (0.33) | GABRA5 | |
| SCHEMBL23905406 | 0.85 | GABRA5 (0.34) | GABRA5SSTR5KCNH2MAPT | |
| SCHEMBL23904864 | 0.85 | GABRA5 (0.31) | GABRA5AR | |
| SCHEMBL23959004 | 0.84 | CFTR (0.35) | GABRA5SSTR5KCNH2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | GABRA5 3773/4885SSTR5 1379/4885KCNH2 3702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.